Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27587689 | 0.90 | KMT2A (0.45) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL27587692 | 0.90 | KMT2A (0.45) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL30683563 | 0.89 | KMT2A (0.46) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL27944082 | 0.89 | KMT2A (0.46) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL29019477 | 0.89 | KMT2A (0.46) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL29089883 | 0.89 | KMT2A (0.46) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL28207071 | 0.88 | PPARG (0.40) | KMT2AFABP5FABP7CASP3 | |
| SCHEMBL4460611 | 0.86 | FABP5 (0.44) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL29019478 | 0.86 | FABP5 (0.44) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL30620282 | 0.85 | KMT2A (0.43) | KMT2AFABP5FABP7CASP3CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858358-B2 | S1PR2 antagonists and uses therefor | DALHOUSIE UNIVERSITY (CA) | 2020-12-08 | — | — | US | disclosed |
| US-20200347058-A1 | S1PR2 ANTAGONISTS AND USES THEREFOR | DALHOUSIE UNIVERSITY (CA) | 2020-11-05 | — | — | US | disclosed |
| US-10487082-B2 | S1PR2 antagonists and uses therefor | DALHOUSIE UNIVERSITY (CA) | 2019-11-26 | — | — | US | disclosed |
| US-20190169187-A1 | S1PR2 ANTAGONISTS AND USES THEREFOR | DALHOUSIE UNIVERSITY (CA) | 2019-06-06 | — | — | US | disclosed |
| US-20190127372-A1 | S1PR2 ANTAGONISTS AND USES THEREFOR | DALHOUSIE UNIVERSITY (CA) | 2019-05-02 | — | — | US | disclosed |
| US-20180141942-A1 | S1PR2 ANTAGONISTS AND USES THEREFOR | DALHOUSIE UNIVERSITY (CA) | 2018-05-24 | — | — | US | disclosed |
| EP-3298014-A1 | S1PR2 ANTAGONISTS AND USES THEREFOR | Dalhousie University (CA) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016191872-A1 | S1PR2 ANTAGONISTS AND USES THEREFOR | DALHOUSIE UNIVERSITY (CA) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858358-B2 | S1PR2 antagonists and uses therefor | S1PR2, S1PR4, S1PR1 | KMT2A 1952/4885FABP5 2016/4885FABP7 1613/4885 |
| US-20190127372-A1 | S1PR2 ANTAGONISTS AND USES THEREFOR | S1PR2, S1PR4, S1PR1 | KMT2A 848/4885FABP5 1541/4885FABP7 987/4885 |
| US-20190169187-A1 | S1PR2 ANTAGONISTS AND USES THEREFOR | S1PR2, S1PR4, S1PR3 | KMT2A 2473/4885FABP5 1628/4885FABP7 1269/4885 |
| US-20200347058-A1 | S1PR2 ANTAGONISTS AND USES THEREFOR | S1PR2, S1PR4, S1PR1 | KMT2A 848/4885FABP5 1541/4885FABP7 987/4885 |
| US-20180141942-A1 | S1PR2 ANTAGONISTS AND USES THEREFOR | S1PR2, S1PR4, S1PR1 | KMT2A 848/4885FABP5 1541/4885FABP7 987/4885 |
| US-10487082-B2 | S1PR2 antagonists and uses therefor | S1PR2, S1PR4, S1PR3 | KMT2A 2473/4885FABP5 1628/4885FABP7 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.